Stockreport

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc.  (ELTX) 
PDF ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-g [Read more]